Riskpilot← Back to searchSign inGet full accessEQUINOSE HOLDING ApS
APSActiveCVR 28324898Nobisvej 28Manufacture of medical and dental instruments and supplies · NACE 3250Est. 20050 employees
Revenue 2024
DKK 0
EBITDA margin
—
-353% vs 2023
Equity ratio
-466.4%
Financial strength
Net profit 2024
DKK -10K
-352% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK -11K | -353% |
| Net profit | DKK -10K | -352% |
| Total assets | DKK 4K | -76% |
| Equity | DKK -21K | -101% |
| Employees | 0 | — |
Legal name
EQUINOSE HOLDING ApS
CVR number
28324898
Legal form
Anpartsselskab
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
1. januar 2005
Share capital
DKK 125.000
Employees
0
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren.
Company purpose
Selskabets formål er at besidde anparter og aktier samt beslægtet virksomhed dermed.
Address
Nobisvej 28
Phone
+4561787787
Email
peter@2ottesen.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85 | 76 | 23 | 32 | 83 | 65 | 95 | 37 | 35 | 39 | 36 | 30 | 0 |
| Staff expenses | -20 | -39 | -17 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -24 | -3 | -5 | 7 | -0 | 3 | -2 | -4 | -2 | -4 | -19 | 4 | -11 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -24 | -3 | -5 | 7 | -0 | 3 | -2 | -4 | -2 | -4 | -19 | 4 | -11 |
| Net financials | 0 | -0 | 0 | 0 | 0 | 0 | -80 | 0 | -0 | -0 | -0 | 0 | 0 |
| Profit before tax | -24 | -3 | -5 | 7 | -0 | 3 | -82 | -4 | -2 | -4 | -19 | 4 | -10 |
| Tax | -10 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -14 | -3 | -5 | 7 | -0 | 3 | -82 | -4 | -2 | -4 | -19 | 4 | -10 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 97 | 94 | 90 | 106 | 100 | 104 | 32 | 25 | 26 | 35 | 15 | 18 | 4 |
| Equity | 94 | 91 | 87 | 93 | 93 | 96 | 15 | 10 | 9 | 5 | -15 | -10 | -21 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 | 3 | 3 | 13 | 7 | 8 | 18 | 15 | 17 | 30 | 30 | 29 | 25 |
| Total debt | 3 | 3 | 3 | 13 | 7 | 8 | 18 | 15 | 17 | 30 | 30 | 29 | 25 |
EBITDA margin
-1050400.0%
This company
15.8%
Market median
-6648201% vs market
20122024
Equity ratio
-466.4%
This company
38.2%
Market median
-1321% vs market
20122024
Return on equity
-1048200.0%
This company
18.4%
Market median
-5696839% vs market
20122024
Net profit margin
-1048200.0%
This company
8.1%
Market median
-12940841% vs market
20122024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
1.21×
This company
0.62×
Market median
-95% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2005 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EQUINOSE HOLDING ApS 
Wren Bioscience ApSBoard members of EQUINOSE HOLDING ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|